





澳門大學
UNIVERSIDADE DE MACAU
UNIVERSITY OF MACAU



中藥質量研究國家重點實驗室(澳門大學)
Laboratório de Referência do Estado para Investigação de
Qualidade em Medicina Chinesa (Universidade de Macau)
State Key Laboratory of Quality Research in Chinese Medicine
(University of Macau)



中華醫藥研究院
Instituto de Ciências Médicas Chinesas
Institute of Chinese Medical Sciences



1st International Symposium on
Chinese Medicine and Natural Products
1st International Symposium on
Pharmaceutical Sciences

Oct 26-28, 2023
University of Macau, Macao SAR



Table of Contents

About us.....	02
Welcome Message.....	03
Organizing Committee.....	04
Symposium Programme	05
Speaker Biography.....	09
Accommodation	17
Transportation to Campus.....	17
Campus Map.....	18

About us

Institute of Chinese Medical Sciences

The Institute of Chinese Medical Sciences (ICMS) was established in 2002 as the first research-oriented institute in the University of Macau (UM). Over the past 20 years, ICMS has devoted itself to promoting research in Chinese medicine and nurturing top-quality talent, contributing to the social and industrial development of Macao. ICMS currently has an excellent team of 39 academic staff (1 Chair Professor, 2 Distinguished Professors, 12 Full Professors, 14 Associate Professors, and 10 Assistant Professors) and 20 administrative/ technical staff. ICMS has successfully trained over 900 MSc and PhD students, as well as approximately 160 postdoctoral research fellows.

State Key Laboratory of Quality Research in Chinese (University of Macau)

The establishment of the first State Key Laboratory in the field of Chinese medicine was approved by the Ministry of Science and Technology of China at UM in 2010. This laboratory focuses on the systemic quality research of Chinese medicine, including effectiveness, safety, stability, and controllability.



Welcome Message

The Institute of Chinese Medical Sciences (ICMS) / State Key Laboratory of Quality Research in Chinese Medicine (SKL-QRCM) of the University of Macau (UM) is delighted to welcome you to the 1st International Symposium on Chinese Medicine and Natural Products (ISCMNP) & the 1st International Symposium on Pharmaceutical Sciences (ISPS).

The symposium aims to bring together renowned scientists, researchers, and practitioners from around the world to exchange knowledge and insights on the latest advancements in Chinese medicine, natural products, and pharmaceutical sciences. With a focus on promoting interdisciplinary collaboration and innovation, the conference will provide a platform for discussing cutting-edge research, sharing best practices, and exploring future directions in these fields.

On behalf of the Organization Committee, it is our great pleasure to welcome you to participate in this exciting event. We sincerely wish you a fruitful meeting and a pleasant time in Macao.

Xin Chen
Symposium Chair
Distinguished Professor
Director, Institute of Chinese Medical Sciences
Interim Director, State Key Laboratory of
Quality Research in Chinese Medicine
University of Macau

Organizing Committee

Symposium Chair
Xin Chen, MD, PhD
Distinguished Professor
Director, Institute of Chinese Medical Sciences
Interim Director, State Key Laboratory of Quality Research
in Chinese Medicine
University of Macau

Honorary Chair
Yitao Wang
Chair Professor, Institute of Chinese Medical Sciences
Director, Macao Centre for Research and Development in
Chinese Medicine
University of Macau

Organizing Committee Members
Prof. Jiahong Lu, PhD
Prof. Jinjian Lu, PhD
Prof. Shengpeng Wang, PhD
Prof. Jianbo Wan, PhD
Prof. Peng Li, PhD
Prof. Ying Zheng, PhD
Prof. Huanxing Su, PhD
Prof. Xiuping Chen, PhD
Prof. Yuanjia Hu, PhD
Prof. Ligen Lin, PhD

Secretary
Dr. Ting Li
Dr. Xuxu Zhuang
Ms. HioFai Cheang
Ms. Yiting Wang

Symposium Programme

26 th Oct 2023 G002 Lecture Hall, N22 Building, University of Macau		
9:00 - 9:30 Outstanding scientific publication forum: engage with editors of prominent journals	<ul style="list-style-type: none">• Introduction of Guests• Welcome Speech by Prof. Wang Yitao Editor-in-chef ,Chinese Medicine• Group Photo	Host: Prof. Jianbo Wan
9:30-12.30	<p><i>The Journal of Leukocyte Biology: A 68-Year Old Platform That Serves The Needs of The Modern Research Community</i> Xin Chen, Deputy editor, Journal of Leukocyte Biology</p> <p><i>Publish in Wiley Biomedical and Interdisciplinary Journals: From An Editor's Perspective</i> Xiaoyu Zhang, Publisher, Wiley China; Editor, Advanced Science</p> <p><i>Journal of Pharmaceutical Analysis: High-quality Development and Academic Content Dissemination Pathways</i> Yanming Zhang, Deputy Editor-in-Chief, Journal of Pharmaceutical Analysis</p> <p><i>CJNM: A History of the Young Editorial Team</i> Zuoqi Ding, Director of Editorial Office, Chinese Journal of Natural Medicine</p> <p><i>From "1" to "10": Xi'an Jiaotong University's Path to Founding An English-Language Journal</i> Mengjie Wang, Director of Editorial Office, Journal of Pharmaceutical Analysis</p> <p><i>The Chinese Medicine in Journals ——Exploration ofChinese Medicine and Culture</i> Haiying Li, Director of Editorial Office, Chinese Medicine and Culture</p> <p><i>Alliance of Chinese Medicine Journals Empowers High-Quality Development of Journals</i> Yu She, Director, Information Department, China Association of Chinese Medicine</p> <p><i>Aging And DiseaseProfessional Journals and Academic Exchange Platforms in The Field Of Ageing And Disease Research</i> Huanxing Su, Associate Editor, Aging and Disease</p> <p><i>Chinese Medicine, A Journey So Far</i> Jianbo Wan, Director of Editorial Office, Deputy Editor, Chinese Medicine</p>	
12:30-14:00	Lunch	
14:00-16:00	Round-table Discussion	Host: Prof. Jinjian Lu
16:00-17:00	Campus tour of University of Macau	
18:30-21:00	Dinner	

Symposium Programme

27 th Oct 2023 Mr and Mrs Lau Chor Tak Lecture Theatre, (E4-G078), University of Macau		
9:00-9:30 Opening Ceremony	<ul style="list-style-type: none">• Opening Remarks Wei Ge Vice Rector (Research), the University of MacauXin Chen Director, Institute of Chinese Medical Sciences of the University of Macau• Group Photo	Host: Prof. CarolinaUng
9:30-10:15 Keynote speech	<p><i>Activation of Antitumor Immunity by Bacteria-Derived Signals: Pyroptosis & Beyond</i> Feng Shao, Academician, CAS. Beijing Institute of Biological Sciences, Beijing, China</p>	Host: Prof. Xin Chen
10:15-10:30	Tea Break	Lobby of E4
10:30-12:30 Scientific Session 1: Cutting-edge Insights into Molecular Targets for Immunotherapy	<p><i>ECM1 Prevents Activation of Transforming Growth Factor beta, Hepatic Stellate Cells, and Fibrogenesis in Mice</i> Bing Sun, Professor, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Beijing, China</p> <p><i>Myeloid Immune Checkpoints for Cancer Immunotherapy</i> Youhai Chen, Chair Professor and Dean, Faculty of Pharmaceutical Sciences, Shenzhen Institute of Advanced Technology, China</p> <p><i>Therapeutically Targeting Human Cytokine Release Syndrome</i> Xiaoyu Hu, Professor, Institute for Immunology, Tsinghua University, Beijing, China</p> <p><i>Small-Molecule STING Agonists:Challenges and Up-Downs</i> Ao Zhang, Professor, Dean of School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China</p> <p><i>IL-4 induced non-canonical trained immunity in macrophages</i> Shih-chin Cheng, Professor, School of Life Science, Xiamen University, Xiamen, China</p>	Host:Prof. Xin Chen Prof. Shih-chin Cheng
12:30-14:00	Lunch	Next Kitchen, UM
12:30-14:00	Poster Session	Lobby of E4

Symposium Programme

14:00-15:30 Scientific Session 2: Novel Technologies for Ensuring the Quality of Traditional Chinese Medicine	<p>Targeting Molecule Discovery of Polysaccharides from Herbs Kan Ding, Professor, Director of Zhongshan Institute of Drug Discovery, CAS, China</p> <p>Deciphering the Wisdom of Traditional Chinese Medicine for Aging-associated Neurodegenerative Diseases Min Li, Professor, Director of Mr. & Mrs. Ko Chi Ming Centre for Parkinson's Disease Research, Hong Kong Baptist University, Hong Kong</p> <p>The Multifaceted Roles of Neutrophils in the Tumor Microenvironment: Potential Use of Herbal Medicines Jinbong Park, Assistant Professor, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea</p> <p>Discovery of Novel Modulatory Target for Aging-related Rheumatoid Arthritis Vincent Kam Wai Wong, Associate Professor, State Key Laboratory of Quality Research in Chinese Medicine(MUST), Macau University of Science and Technology</p>	Host: Prof. Jiahong Lu Prof. Vincent Kam Wai Wong
15:30-15:50	Tea Break	Lobby of E4
15:50-17:30 Scientific Session 3: Progress in Clinical Research and Drug Regulation	<p>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel Group Clinical Trial of Zhizhu Kuanzhong Capsule in Treating Patients with Postprandial Distress Syndrome of Functional Dyspepsia Lidan Zhong, Associate Professor, Director, NTU Chinese Medicine Clinic, Nanyang Technological University, Singapore</p> <p>The Health Wisdom in TCM Classics and Its Applications Ping Wang, Professor, Hubei University of Chinese Medicine, Wuhan, China</p> <p>Integrating Bioactive Compounds of Chinese Herb into Cancer Research Yabing Cao, Director of Department of Oncology Kiang Wu Hospital, Macao</p> <p>Big Data Analysis of Patents and its Applications in Pharmaceutical Research and Development Yuanjia Hu, Professor, Institute of Chinese Medical Sciences, University of Macau, Macao</p>	Host: Prof. Yuanjia Hu Dr. Yabing Cao
18:00-20:00	Dinner	LAUREL Restaurant

Symposium Programme

28th Oct 2023 Mr and Mrs Lau Chor Tak Lecture Theatre, (E4-G078), University of Macau		
9:00-10:50 Scientific Session 4: Frontier in drug discovery	<p>Efficient Synthesis of Taxol via Multicomponent Reaction Wenhao Hu, Professor, Director of School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China</p> <p>A Fun Journey of Drug Discovery in Industry: Exploiting the Immune System for Cancer Immunotherapy Nanhai He, Vice President, Drug Discovery, Adlai Nortye USA Inc., North Brunswick, NJ, US</p> <p>Advances in Technologies for Target Discovery of Natural Products Kewu Zeng, Professor, School of Pharmaceutical Sciences, Peking University, Beijing, China</p> <p>Synergy in Herbal Medicine Formulas: Concept, Methodological Approaches and Applications Phoebe Xian Zhou, Research Support Program Fellow, NICM Health Research Institute, Western Sydney University</p> <p>Neuronal Protective Effect of Artemisinins and its Implication in the Treatment of Alzheimer's Disease Wenhua Zheng, Professor, Faculty of Health Science, University of Macau</p>	Host: Prof. Jinjian Lu Prof. Wenhua Zheng
10:50-11:10	Tea Break	
11:10-12:30 Scientific Session 5: Innovations in Pharmaceutical Products and Drug Delivery	<p>One Stone Four Birds: Application Of Ginsenosides to Prepare Multifunctional Liposomal Delivery System for Cancer Therapy Jianxin Wang, Professor, School of Pharmacy, Fudan University, Shanghai, China</p> <p>Brain Targeting Drug Delivery System Chen Jiang, Professor, School of Pharmacy, Fudan University, Shanghai, China</p> <p>Effective Vaccination and Immunomodulation Mediated by Polymeric Microneedles Xun Sun, Professor, West China School of Pharmacy, Sichuan University, Chengdu, China</p> <p>Nanocarriers of Active Ingredients from Chinese Medicine for Cancer Therapy Meiwan Chen, Professor, Institute of Chinese Medical Sciences, University of Macau, Macao</p>	Host: Prof. Meiwan Chen Prof. Xun Sun
12:30-12:50	Announcement of SLB/JLB Trainee Awards Closing Ceremony	
12:50-13:30	Lunch	Next Kitchen, UM
14:00	Departure	

Speaker Biography



Feng Shao

Dr. Feng Shao is an investigator and deputy director at National Institute of Biological Sciences (NIBS), Beijing, China. He was a chemistry undergraduate of Peking University (1991-1996) and obtained his PhD with Dr. Jack E. Dixon from University of Michigan in 2003. Prior to returning to China in 2005 to assume an assistant investigator at NIBS, he was a Damon Runyon Postdoc Research Fellow at Harvard Medical School. Dr. Shao was promoted to become an associate investigator in 2009 and a full investigator in 2012 at NIBS. He has also been appointed as an Endowed Chair Professor of Tsinghua University since 2020.

Dr. Shao's research lies at the interface between bacterial pathogen and host inflammation. He identified most of the known cytosolic receptors for bacterial molecules, including caspase-11/4/5 for LPS and ALPK1 for ADP-heptose in LPS biosynthesis. He also identified gasdermin-D (GSDMD) whose cleavage by caspase-1/4/5/11 determines pyroptosis, critical for septic shock and other inflammatory diseases. His research establishes the gasdermin family of pore-forming proteins, re-defining pyroptosis as gasdermin-mediated programmed necrosis. Among the family, GSDME is activated by caspase-3, which occurs mostly in noncancer cells and contributes to toxicity of chemotherapy drugs. His most recent work demonstrates that pyroptosis is a critical mechanism underlying lymphocyte cytotoxicity and gasdermin activation can stimulate potent antitumor immunity.



Bing Sun

Prof. Bing Sun is from Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (in Shanghai, China) and was a chief, Lab of Molecular Immunology. He has MD and Ph.D. He has been working on T helper cell differentiation and its functions in autoimmune diseases. He has identified that Trim-30a, Dec2 and ECM1 are key molecules in controlling innate immunity and Th2 cell-mediated responses (Nature Immunology 2008, 2009, 2011 and PNAS 2018). Currently the study is mainly to focus on the interaction of Th2 cells and ILC2 in asthma diseases (Nature Immunology 2022). In translational research, his group also developed Single-cell RT-PCR to raise full-human mAb against Covid-19 (Nature Microbiology 2022). He uncovered ECM1 servers as a key hemostasis molecule to control liver fibrosis (Gastroenterology, 2019). He was as a postdoctoral fellow at NIH, USA from 1994-1999. Now he is vice president of Chinese Society of Immunology.



Youhai Chen

Dr Chen Youhai, PhD in Immunology, Member of Academia Europaea, Fellow of American Institute of Medical and Biological Engineering (AIMBE), National Distinguished Professor, Changjiang Scholar of Ministry of Education of China, and Distinguished Young Scholar of China Foundation. He is currently a Chair Professor and Dean of the School of Pharmacy, Shenzhen University of Science and Technology, Chinese Academy of Sciences. He was a tenured professor in the Department of Pathology and Laboratory Medicine of the University of Pennsylvania, Chairman of the Teaching Committee of the University of Pennsylvania School of Medicine, and Chairman of the Scientific Committee of the American Multiple Sclerosis Foundation. He is mainly engaged in the research of cancer and inflammation mechanism and therapy, and has made remarkable achievements in many fields such as regulation of immune response, pathogenesis and treatment of immune diseases, and application of new immune checkpoint drugs in cancer therapy. He has published more than 160 academic papers (H-factor 68; total citations >20,000) in leading international journals such as Science, Cell, Nature, Nature Immunology, Nature Cancer, and others. He has been selected for the Lifetime Impact List of the top 1% of the world's leading scientists, and is a Fellow of the Kunkel Society (Elected Member) and a recipient of the Colyton Prize.

Speaker Biography



Xiaoyu Hu

Xiaoyu Hu received her Bachelor of Medicine degree from Peking University and obtained her Ph.D. degree in immunology from Cornell University. Currently she is Professor and Director at Institute for Immunology, Tsinghua University.

Dr. Hu's research aims to better understand molecular mechanisms governing functionality of two key cell types involved in host defense and inflammatory responses, macrophages and intestinal epithelial cells (IECs). One focus of Dr. Hu's laboratory is to uncover transcriptional, translational and metabolic mechanisms that regulate macrophage and IEC responses to pathogenic and inflammatory cues. Dr. Hu's work has been funded by agencies including National Natural Science Foundation of China (NSFC), Minister of Science and Technology of China, U.S. National Institutes of Health (NIH R01), U.K. Royal Society, American College of Rheumatology and Lupus Research Institute and has been reported by news media such as Time Online.

Dr. Hu has authored over 60 publications including corresponding-author research articles in journals such as Immunity, Nature Immunology, Cell Host & Microbe, Science Translational Medicine, Journal of Experimental Medicine, and Nature Communications and book chapters (h-index = 34 by Google scholar). She is the recipient of multiple awards including Christina Fleischmann Award to Young Women Investigators from International Cytokine & Interferon Society, Distinguished Young Investigator Award from NSFC, Newton Advanced Fellowship from the U.K. Royal Society and Young Scholar Award from Arthritis Foundation. Dr. Hu also serves in editorial boards of journals including Science Advances, eLife, Trends in Immunology and composed commentary articles for journal such as Immunity. She actively advocates for status and rights of female scientists by serving in diversity panels for organizations such as Society of Leukocyte Biology and composing opinion essays for journals such as Nature Immunology.



Ao Zhang

Zhang Ao was awarded the Ph.D. diploma in Organic Chemistry in 2000, he joined Professor Alan P. Kozikowski's Drug Discovery Group at Georgetown University Medical Center as a Postdoctoral Fellow. In 2002, he joined Professor John L. Neumeyer's Medicinal Chemistry Program as a Research Investigator at McLean Hospital, Harvard Medical School. He was promoted to Instructor at Harvard Medical School in 2003 and Assistant Director of the Medicinal Chemistry Program at McLean Hospital in 2004. He was awarded Alfred Pope Young Investigator Award in 2004 and Adam Corneel Young Investigator Award in 2005 from Harvard Medical School. In 2006 he received the Hundred Talent Project award from the Chinese Academy of Sciences, and became the Professor of Medicinal Chemistry at Shanghai Institute of Materia Medica (SIMM). In 2011, he was awarded the Distinguished Young Investigator Award from Chinese Natural Science Foundation. His research interests include the design and synthesis of novel small molecules as structural and functional probes for the diagnosis and treatment of brain disorders and cancer by using the state-of-art medicinal chemistry strategy. He has authored or co-authored over 80 publications and 40 patents. Several drug candidates from his research group are now under preclinical studies.



Shih-Chin Cheng

Dr. Shih-Chin Cheng, Professor at Xiamen University's School of Life Sciences earned his Ph.D. from Radboud University Nijmegen in the Netherlands under the mentorship of Professor Mihai Netea. After postdoctoral research at Harvard Medical School and the Broad Institute, Dr. Cheng joined National Tsing Hua University in Taiwan and later Xiamen University.

His research centers on the regulation of innate immune cells, particularly in trained immunity during infections and cancer. His work has been published in esteemed journals, such as Science, Nature Immunology, and Cell Metabolism. Dr. Cheng's current investigations focus on the interplay between metabolic reprogramming and epigenetic modifications in innate immune cells, the role of trained immunity in inflammatory bowel diseases and its interaction with gut microbiota, and the potential of trained immunity in anti-tumor responses.

Speaker Biography



Kan Ding

DING Kan, Ph.D, Professor, Ph.D candidate supervisor, Principal Investigator in Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and Zhongshan Institute for Drug Discovery, SIMM, CAS. Dr. DING Kan's main research interests focus on the structure and function, structure-activity relationship, targeting, and the mechanism underlying action of polysaccharides from traditional Chinese medicine, interaction between bioactive polysaccharide and gut microbiota, and functional mechanism of cell membrane proteoglycan and its related enzymes. In addition, he also tries to discover new target for glycan-based drug discovery and engage in carbohydrate-based drug development.

So far, he has obtained 31 grants, including State Key Program of National Natural Science of China, the National Natural Science Foundation of Science Fund for Distinguished Young Scholars, etc.; and published over 170 papers in international professional journals such as J. Hepatol., Angew. Chem. Int. Ed. Engl., Carbohydr. Polym; and filed more than 60 national and international patents.



Min Li

Prof. Li currently is the Associate Dean and the Director of Double Degree Program of Bachelor of Chinese Medicine & Bachelor of Biomedical Science in the School of Chinese Medicine (SCM), Hong Kong Baptist University (HKBU). Prof. Min LI obtained a bachelor's degree from Henan University of Chinese Medicine in 1985, a master's degree from Guangzhou University of Chinese Medicine in 1988 in China, and a PhD degree from School of Medicine, Tokai University in 2001 in Japan. Prof. Li's group research focuses on the neuroprotective effects and molecular mechanisms of traditional Chinese medicine (TCM) on neurodegenerative diseases, especially on Parkinson's disease (PD), Alzheimer's disease (AD) and Amyotrophic lateral sclerosis (ALS). Prof. Li's group research also including clinical study of the efficacy and safety of TCM in the treatment of PD and AD. Prof. Li was awarded as the distinguished female Chinese medicine practitioner by the China Association of Chinese medicine in 2007, she also received two times of the President Award in HKBU for Excellent Performance in Teaching in 2013 and 2018. Prof. Li has granted various external research grants (GRF, HMRP, ITC etc.) and UGC Teaching and

Learning grants, she published over 160 scientific research papers, over 200 oral or poster presentations in the international conferences, and over 20 books, as well as her group obtained over 20 US, European and Chinese patents.



Jinbong Park

Dr. Jinbong Park is an emerging KMD-PhD in the field of cancer research, currently affiliated with Kyung Hee University. He majored in Korean Medicine at Kyung Hee University, and completed his MS and PhD in Science of Korean Medicine at the same institution.

Dr. Park's research primarily focuses on neutrophil function in various diseases including but not limited to immune dysfunction, metabolic diseases and several types of cancer. His current effort is largely put on to investigate the recently revealed dual roles of neutrophils in the tumor microenvironment. As a Korean Medicine doctor, he also conducts studies to explore novel therapeutic approaches based on herbal medicine that could inhibit cancer progression.

Speaker Biography



Vincent Wong

Prof. Vincent Kam Wai Wong received his Ph.D. Degree from the University of Hong Kong and then worked as post-doctoral research fellow and RAP in Hong Kong Baptist University. From 2011, he has been starting his research career from assistant professor to full professor in State Key Laboratory of Macau University of Science and Technology engaging in the research field of anti-inflammation and anti-cancer.

Prof. Vincent Wong research focus on relationship between autophagy and multidrug-resistant, apoptosis-resistant anti-tumor effect via SERCA inhibition and AMPK activation. Recently, he deeply interested in the involvement of p53 and P-glycoprotein in drug-resistant phenotype of rheumatoid arthritis. Notably, he recently unraveled the etiology behind the elevated incidence of rheumatoid arthritis in middle-aged and elderly populations and successfully published the works in Nature Communications. Furthermore, he has published over 170 peer-reviewed SCI journals and obtained more than 40 US, Australia and China patents. He is one of the world top 2% scientists announced by Standard University.




Lidan Zhong

Linda Zhong, MD., Ph.D is currently Associate Professor and Director of Chinese Medicine and Biomedical Sciences at Nanyang Technological University, Singapore. Equipped with Bachelor in Chinese Medicine, Master of Doctor (MD) in integrative and Chinese Medicine in Shanghai University of TCM, and Doctor of Philosophy (PhD) in Chinese Medicine clinical research at the University of Hong Kong (HKU), Dr. Zhong has worked in Chinese Medicine education, research, and service for more than 20 years.

She has designed and conducted more than 50 clinical studies with broad scope of diseases and interventions and successfully applied different levels of grants from government. Totally, she has obtained 19 clinical research projects as Principal Investigator and edited 10 books of Chinese Medicine and Integrated Medicine.

Her research focuses mainly on integrative medicine and globalization of Chinese Medicine. She is also a Visiting Professor of Integrative Medicine Centre, the University of Toronto, and Visiting Fellow of Australian Research Centre for Complementary and Integrative Medicine, the University of Technology Sydney. She serves as the Vice President of Hong Kong Association for Integration of Chinese-Western Medicine. In 2020, she was awarded a Qi Huang Young Scholar by the State Administration of Traditional Chinese Medicine in recognition of her excellence in clinical practice and studies of Chinese medicine.




Ping Wang

Wang Ping, a level-2 professor (professors in China fall into 4 levels) and chief physician, is one of the first group of outstanding Qi-Huang Scholars recognized by the national government, and he enjoys the privilege of being an expert receiving a special allowance from the State Council. He also served as the former vice president of Hubei University of Chinese Medicine and currently serve as the director of the Ministry of Education's Engineering Research Center for Traditional Chinese Medicine (TCM) Protection Techniques and New Product Development for Elderly Brain Health, director of the national administration bureau of TCM's key research laboratory on elderly dementia, and head of the internal medicine discipline of the Yellow Emperor's Inner Canon. He is also the director of the Institute of Geriatric Medicine and the chief scientist of Hubei Shizhen Laboratory. In addition, he serves as the executive director of the China Association of Chinese Medicine and the chairman of the Li Shizhen medical research and application professional committee of the World Federation of Chinese Medicine. He has been awarded as an inheritor of the "Qihuang Traditional Chinese Medicine Inheritance and Development Award" for the third session, recognized as a mentor for academic experience in the sixth and seventh sessions of the National Renowned Senior TCM Expert

Program, and selected as a top-level candidate for leading medical talents in Hubei Province. He has led 15 national-level research projects, including one project under the National Key Research and Development Program for the prevention and treatment of chronic insomnia using TCM, two key projects funded by the National Natural Science Foundation, and two projects of Major New Drug Development funded by the Ministry of Science and Technology. He has also received one first-class national teaching achievement award and three times of provincial-level science and technology awards of first and second class, respectively. And he has edited 16 textbooks and monographs and published over 300 research papers.

Speaker Biography



Yabing Cao

Dr. Yabing Cao is now working at Kiang Wu Hospital, department of oncology, where he helps to establish the chemotherapy and target therapy in KWH. He pursue his MSc study in Medical Oncology in Sun Yat-sen University cancer center. He further completed his PhD degree in the Department of Medical Oncology, Sun Yat-sen University cancer center. When he was Ph.D candidate, he got the first scholarship from National Scholarship Council, which help him pursue the most advanced knowledge in cancer research and treatment in University of Texas MD Anderson Cancer Center (MDACC).

As a clinical oncologist, he is also interested in cancer research. He won the FDCT grant in 2017, which is focus on PD-1 therapy in EBV positive cancers and lung cancers. He also won the 3rd place Scientific and technological progress award of Macau in 2014, and National Top-stat on Oncology Research in 2013. He has many published papers and he was editor of Journal of Thoracic Oncology and MBS. Now he is conducting many real word study on target therapies in lung cancer, breast cancer and melanoma.



Yuanjia Hu

Dr. Yuanjia Hu is a Professor of State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, Associate Head of the Department of Public Health and Medicinal Administration, Faculty of Health Sciences, and the Director of Centre for Pharmaceutical Regulatory Sciences, University of Macau. His research primarily focuses on providing informatics solutions to critical challenges in the process of drug discovery through the multidisciplinary lens of administration and technology. He has led 25 domestic and foreign scientific research projects, and published more than 150 academic papers in peer-reviewed journals such as Nature Biotechnology, Briefings in Bioinformatics, Pharmacological Research. He is also Commissioner of the Policy Committee in China Pharmaceutical Innovation and Research Development Association, Project Researcher in the Research Center of National Drug Policy & Ecosystem, Deputy Secretary-General in Specialty Committee on Network Pharmacology of World Federation of Chinese Medicine Societies, and Executive Council Commissioner of the Commission on Network Pharmacology in Chinese Pharmacological Society.



Wenhao Hu

Wenhao Hu is a professor and dean of the School of Pharmacy at Sun Yat-sen University. He is a recipient of the National Outstanding Youth Fund. Prof Hu received his BSc degree from Sichuan University (1987), MSc degree from Chengdu Institute of Organic Chemistry, Chinese Academy of Sciences (1990), and PhD degree from The Hong Kong Polytechnic University (1998, supervised by Academician Xinzhong Chen), followed by postdoctoral fellowships at the University of Arizona, USA (1998-2002). After working as a senior researcher at Genesoft and Bristol-Myers Squibb in the US, Prof Hu returned to China in 2006 and joined the East China Normal University as a Professor in the Department of Chemistry, a Distinguished Professor of "Oriental Scholars" of Shanghai Universities (2009-2016), and a Professor in the Shanghai Molecular Therapeutics and New Drug Discovery Institute (2009-2016), where he was a member. He joined East China Normal University in 2006 as Professor of Department of Chemistry, "Oriental Scholar" Distinguished Professor of Shanghai University (2009-2016) and Director of Shanghai Engineering Research Centre for Molecular Therapy and New Drug Creation (2011-2016), and then joined Sun Yat-sen University as Professor and Dean of School of Pharmacy, Director of Guangdong Provincial Key Laboratory of Chiral Molecules and Drug

Discovery (from 2019), and Director of Guangdong Provincial Key Laboratory of Chiral Molecules and Drug Discovery. Currently, he is a member of the Eighth Pharmacy Discipline Review Group of the Academic Degrees Committee of the State Council, a member of the Teaching Steering Committee of Pharmacy in Colleges and Universities under the Ministry of Education, and the vice president of Guangdong Pharmaceutical Society. He has received more than twenty awards at home and abroad, such as the First Prize of Natural Science of Shanghai (2016), the Second Prize of Natural Science of the Ministry of Education (2010), the Expert Enjoying the Special Allowance of the State Council (2016), and a candidate of the National Project of One Hundred and Ten Million Talents, and a young and middle-aged expert with outstanding contributions. His research interests focus on organic synthesis methodology, multi-component reaction, new drug development and drug synthesis process, etc. So far, he has been published in Nature Chemistry, Nature Communications, Science Advances, Journal of the American Chemical Society, Journal of the American Chemical Society. He has published more than 220 papers in Nature Chemistry, Nature Communications, Science Advances, Journal of the American Chemical Society, Angewandte Chemie International Edition and Journal of Medicinal Chemistry, with more than 5000 citations, and has applied for more than 100 patents (more than 40 granted).

Speaker Biography



Nanhai He

Dr. He joined Adlai Nortye in 2015, and currently serves as Head of Drug Discovery that is responsible for the management of multiple discovery departments including Biosciences, Medicinal Chemistry, Translational Medicine. Dr. He received his B.S and M.S. degrees at Xiamen University and Ph.D. at University of California, Berkeley, with a post-doc training at the Salk Institute. He was once instructed by Dr. Xun Xu, a member of the Chinese Academy of Engineering, and Dr. Ronald M. Evans, a member of the US National Academy of Sciences. After taking the lead in Adlai Nortye's drug discovery, Dr. He has constructed multiple drug screening platforms, built the innovative internal I/O pipeline and facilitated the clinical development of multiple preclinical programs. With more than 20 years of research and development experiences, Dr. He brings his expertise in immunology, metabolism and antibody engineering to the area of drug discovery and aligns with the company's mission to save patient lives.



Kewu Zeng

Dr. Ke-Wu Zeng is currently working as professor in School of Pharmaceutical Sciences, Peking University. Dr. Zeng has received the National Science Fund for Distinguished Young Scholars and selected for the National Outstanding Youth Fund and the Youth Changjiang Scholar. Dr. Zeng has proposed the concept of "Traditional Chinese Medicine-Chemistry Biology". His research interests mainly focus on the pharmacological target identification of bioactive natural products from traditional medicine. Zeng has published about 130 research papers in PNAS, Sci Adv, Adv Sci, ACS Cent Sci, ACS Nano, STTT, etc. His researches has been reported by NSFC and ScienceNet, and selected as China's Top Ten Medical Advances for 2017 and Top Ten Traditional Chinese Medicine Advances for 2022. Zeng has received several science and technology awards from ministry of education and CAITWM. He has managed 12 research projects such as NSFC, NKRD, international research cooperation programs. Zeng has obtained 10 invention patents with authorization or acceptance. Moreover, Zeng is taking on the positions of academic duties in World Federation of Chinese Medicine Societies and Chinese pharmacological society.



Dennis Chang

Professor Dennis Chang is the Director of NICM Health Research Institute at Western Sydney University, Australia. He is recognised internationally as a leading researcher in pharmacology and clinical research of natural and traditional medicine. Professor Chang has led a number of significant multi-centre clinical trials to evaluate herbal medicine, yoga and tai chi for the treatment of vascular dementia, mild cognitive impairment, coronary heart disease, metabolic syndrome and type 2 diabetes. Professor Chang has conducted numerous laboratory-based studies to evaluate pharmacokinetic/bioavailability profiles and mechanisms of action of herbal medicine. His research has been widely published in high-quality international medical journals with > 120 peer-reviewed journal articles. Professor Chang has also led the Institute's international engagement program, building and sustaining relationships and long-term partnerships with many prestigious universities, research organisations and pharmaceutical/complementary medicine industry around the world.

Speaker Biography



Wenhua Zheng

Zheng Wenhua, professor and principal investigator at the University of Macau, a Fellow of the Royal Society of Biology and the Section Editor of Springer's main reference book, "Encyclopedia of Gerontology and Population Aging." Professor Zheng is currently the vice chairman of the World Federation of Chinese Medicine Societies (WFCMS) Geriatrics Professional Committee, the deputy director of the Guangdong-Hong Kong-Macao University Psychiatry and Neurological Diseases Alliance, the Standing Committee Member of the WFCMS Clinical Drug Safety Research Professional Committee, and the Epigenetics Committee of the Chinese Pharmacological Society, Vice Chairman of Macau Pharmacological Society. Professor Zheng studies neuropharmacology and neurodegenerative diseases. He has published over 150 papers and 8 English book chapters.



Jianxin Wang

Professor Jianxin Wang received his Ph.D. in pharmaceutics from West China University of Medical Sciences in 1999. He has been a professor in School of Pharmacy at Fudan University since 2012 and appointed as vice dean from 2012 to 2019. He worked as a visiting scholar in College of Pharmacy, University of Michigan from 2009 to 2010. His research interest areas include pathology features based targeting drug livery, drug transport through biological barriers, and the development of novel dosage form and new preparations. He has been the principle investigator of more than 30 projects funded by the government. He has published more than 200 papers, edited or co-edited 18 books, and holds more than 20 issued patents.



Chen Jiang

Prof. Chen Jiang graduated from Shanghai Medicine University (China) and Kyushu University (Japan). She obtained his Ph.D. in Pharmaceutical Science from Kyushu University in 2003. She was appointed as a staff member at Fudan University thereafter and promoted to professor in 2010. During that period she became involved in Drug Delivery Systems and received National Science Fund for Distinguished Young Scholars (2014). Prof. Jiang's research interests mainly cover functional materials and targeting molecules for drug delivery system targeting to brain and tumours.

Speaker Biography



Xun Sun

Prof. Xun Sun is the Director & Professor of Department of Pharmaceutics, West China School of Pharmacy, Sichuan University. After postdoctoral training at University of Pennsylvania and University of Michigan, she joined the faculty of Sichuan University in 2008 and became a professor in 2012. Prof. Sun's current research centers on the delivery of vaccines and nucleic acid-based therapeutics, including the transdermal and mucosal delivery of these biopharmaceuticals. She has published more than 100 peer-reviewed papers as the corresponding author. She filed 42 patents and contributed chapters to 10 books. She is the Associate Editor of Journal of Controlled Release, Molecular Therapy and Pharmaceutical Fronts. She also serves as the member of Chinese Pharmacopoeia Commission. Prof. Sun was the recipient of the National Science Fund for Distinguished Young Scholars, the Royal Society Newton Advanced Fellowship (UK), the Shulan Medical Prize, the second prize of National Scientific and Technological Progress Award.



Meiwan Chen

Prof. Meiwan Chen's research focuses on biomaterial and nanomedicine, especially on development of novel drug delivery systems for active ingredients of Chinese medicine. The research ranges from design and synthesis of novel lipidic and polymeric carriers to mechanistic understanding of delivery barriers and to in vivo studies of relevant tumor models and rheumatoid arthritis. The emphasis is on improving the efficacy of chemotherapeutics that have poor water-solubility, fast metabolism, non-selectivity, and drug resistance. Leveraging on the expertise and resources of the SKL of Quality Research in Chinese Medicine at the University of Macau, the lab also develops nanomedicines combining Chinese and Western medicinal compounds for synergistic effects.

Prof. Chen has published 117 top-tier SCI journals (25 papers with IF>10, 78 papers with IF>5) as the first/corresponding author, including Advanced Materials, ACS Nano, Nano Letters, Biomaterials, and many more. Her publications have been cited >10000 times, with an h-index of 57, with 5 being recognized internationally as "ESI highly cited papers". She has been in charge 20 projects funded by NSFC as well as the Macau Fund. She also published 6 book chapters and 9 patents. She was awarded the Excellent Young Scientist Fund by National Natural Science Foundation of China in 2019 (the first time opened for HK and Macao applicants) and 'Qi Huang' Youth Scholarship by the State Administration of TCM, China in 2020. She was elected as a Fellow of the Royal Society of Chemistry (FRSC) in 2022. She won the Natural Science Award (2nd/2nd/3rd Class) in 2012/2014/2018 and the Science and Technology Progress Award (3rd Class) in 2022, as awarded by the Macao Science and Technology Award.


Accommodation

Rooms at the UM Guest House (N1) at UM are available from 26 to 28 Oct 2023 (both dates inclusive) on a first-come, first-served basis.


Rooms




Single Room




Superior Single Room



Shared Room



Accessible Room



VIP Suite


Facilities



Activity Room



Meeting Room



N1 Fitness Room



Front Desk Area

Transportation to Campus

How to get to UM:

You may take taxi or public bus to the E4-劉少榮樓 Anthony Lau Building (Bus Stop: T552 Central Teaching Building (澳大/中央教學樓)).

Currently, there are seven public bus routes connecting to campus, which are

71, 72, 73, 71S, 73S, 701X, N6 (Overnight bus)

For details of those bus routes and the ways to the University of Macau, please refer to the website of DSAT: http://www.dsat.gov.mo/bus/en/bus_service.aspx

More details of public transportation could also be found on: <https://sfs.cmdo.um.edu.mo/our-services/transport-services/public-transport>

Campus Map

